Skip to main
BCAX
BCAX logo

BCAX Stock Forecast & Price Target

BCAX Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Bicara Therapeutics Inc's innovative approach with ficerafusp alfa, a bifunctional antibody targeting EGFR and TGF-beta, positions the company favorably in a burgeoning $4-5 billion market for solid tumor therapies, which could support multiple blockbuster drugs. The reduction in target enrollment for the FORTIFI-HN01 trial is expected to lower costs and expedite the timeline to market, alleviating investor concerns regarding competition with petosemtamab. Moreover, promising Phase 1b data showcasing a 9.8-month median progression-free survival for HPV-negative patients suggests a competitive edge in response durability, reinforced by higher complete response rates and favorable data on duration of response and median overall survival.

Bears say

Bicara Therapeutics Inc. faces significant risks regarding the efficacy and safety of its lead program, ficerafusp alfa, which may impede its development and hinder potential market entry. The company also encounters commercial challenges from both existing and emerging therapies, further complicating its competitive landscape in the biopharmaceutical industry. Additionally, the delayed progress in securing breakthrough therapy designation (BTD) signals potential regulatory hurdles, with crucial milestones not expected until early 2026, raising concerns about the overall viability of the company's commercialization strategy.

BCAX has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicara Therapeutics Inc (BCAX) Forecast

Analysts have given BCAX a Buy based on their latest research and market trends.

According to 2 analysts, BCAX has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicara Therapeutics Inc (BCAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.